20. Jacot JL, Looft-Wilson RC, Yousefieh N, Lattanzio FA, Hosseini A. The Vasoproliferative Phase in the Oxygen-Induced Rat Model of Retinopathy of Prematurity Exhibits Concomitant Increased Expression of VEGF164 and Phosphorylation of eNOS at Serine 1179. Journal of Clinical Pathology and Laboratory Medicine 2016.
19. Jacot JL, Sherris D. Role of mTOR inhibitors in the pathophysiology of diabetic retinopathy. Journal of Ophthalmology. 2011, Article ID 589813, pages 19.
17. Van Zandt MC, Jones ML, Gunn DE, Geraci LS, Jones H, Sawicki DR, Sredy J, Jacot JL, DiCioccio T, Petrova T, Mitschler A, Podjarny AD. Discovery of 3-[(4,5,7-Trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (Lidorestat) and Cogeners as Highly Potent and Selective Inhibitors of Aldose Reductase for Treatment of Chronic Diabetic Complications. J. Med. Chem 2005, 48, 3141-3152.
16. Glover JP, Jacot JL, Basso MD, Hohman TC, Robison, WG Jr. Retinal capillary dilation:Early diabetic-like retinopathy in the galactose-fed rat model. Journal Ocular Pharmacol & Therapeutics,16 (2):167-172, 2000.
15. Robison, WG Jr, Jacot JL, Katz ML, Glover JP. Retinal Vascular Changes Induced by the Oxidative Stress of Alpha-Tocopherol Deficiency Contrasted with Diabetic Microangiopathy. Journal of Ocular Pharmacology & Therapeutics, 16(2):109-120, 2000.
14. Jacot JL, Sredy J. Emerging Therapeutics for Diabetic Retinopathy: Potential Therapies for the New Millennium. Emerging Therapeutic Targets 3(2):307-335, 1999 (Review).
13. Robison WG Jr, Jacot JL, Glover JP, Basso MD, Hohman TC. Diabetic-Like Retinopathy: Early and Late Intervention Therapies in Galactose-Fed Rats. IOVS, 39(10): 1933-1941, 1998.
12. Jacot JL, O'Neill T.J., Scandling D.M., West S.D., McKenzie J.E. Nitric Oxide Modulation of Retinal, Choroidal, and Anterior Uveal Blood Flow in Newborn Piglets.J. Ocular Pharm. & Therap14 (5):473, 1998.
11. Jacot JL, Hosotani H, Glover JP, Lois N, Robison WG Jr. Diabetic-Like Corneal Sensitivity Loss in Galactose-Fed Rats Ameliorated with Aldose Reductase Inhibitors. Journal of Ocular Pharmacol & Therapeutics 14(2):169-180, 1998.
10. Jacot JL, Glover JP, Robison WG Jr. Computer Analysis of Corneal Innervation Density Using a Novel Double Stain in Rat Corneal Whole Mounts. Journal of Anatomy, 191, 191-199, 1997.
9. Robison WG Jr, Laver NM, Jacot JL, Chandler ML, York BM, Glover JP. Efficacy of Treatment After Measurable Diabetic-Like retinopathy In Galactose-Fed Rat. IOVS, 38(6):1066-1073, 1997.
8. Robison WG Jr, Jacot JL, Glover JP. Recent contributions of animal models for elucidating ocular complications of diabetes. Experimental and Clinical Endocrinology & Diabetes. 105 (S03):50-51, 1996.
7. Robison WG Jr and Jacot JL. Educacion Programada a Distancia en Diabetes, Nutricion,Vasculopatia Y Pie Diabetico. Education Profesional Continua a Distancia (EPROCAD). A¤o 1, Modulo 1, 70-72, Oct. 1996.
6. Robison WG Jr, Laver NM, Jacot JL, Glover JP, Basso MD, Blouin P, Hohman TC. Diabetic-Like Retinopathy Ameliorated with the Aldose Reductase Inhibitor WAY-121,509. IOVS, 37(6):1149-1156, 1996.
5. Jacot JL, Laver NM, Glover JP, Lazarous DF, Scheinowitz M, Unger EF, Robison WG Jr. Histological Evaluation of the Canine Retinal Vasculature Following Chronic Systemic Administration of Basic Fibroblast Growth Factor. Journal of Anatomy, 188:349-354, 1996.
4. Robison WG Jr, Laver, NM, Jacot JL, Glover JP. Sorbinil Prevention of Diabetic-Like Retinopathy in the Galactose-Fed Rat Model. (IOVS) Investigative Ophthal & Visual Science, 36(12):2368-2380, 1995.
3. Jacot JL, Glover JP, Robison WG Jr. Improved Gold Chloride Procedure for Optimal Preservation of Nerve Staining in Whole Mounts of Rat Corneas. Biotechnic & Histochemistry, 70(6):277-284, 1995.
2. Robison WG Jr., Jacot JL, Laver NM. Retinopatia Diabetica: Patogenia y Prevencion con Varios Inhibidores de la Aldosa Reductasa. Medico Interamericano, 8:445-449, 1994.
1. Sun JC, Jacot JL, Brenner JI. Sudden Death in Supravalvular Aortic Stenosis. Pediatric Pathology, 12: 751-759, 1992.
Laboratory of mechanisms of ocular diseases with emphasis on diabetic retinopathy, ROP and other angiogenic ocular diseases. Mechanisms of long-term complications of diabetes. Mechanisms of microangiopathies, vasculopathies and angiogenesis. Diabetic corneal complications. Small molecule drug discovery and development.in collaboration with Angioceutics International, LLC.
